Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report

Overview of attention for article published in Frontiers in oncology, August 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 4 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 19,710 followers.

Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report https://t.co/cHypJYYd2I

15 Sep 2023

Reply Repost Favourite

RT @FrontOncology: New research: Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic b…

04 Sep 2023

Reply Repost Favourite

New research: Disitamab Vedotin (RC48) combined with bevacizumab for treatment of HR-negative/HER2-positive metastatic breast cancer with liver and brain involvement: A case report: Background The overexpression of human epidermal growth… #oncology https:

04 Sep 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.